Table 3 Frequency of adverse drug reactions of grade 3/4 severity (highest NCI CTC grade per category and patient)
From: Trastuzumab in advanced breast cancer – a decade of experience in Germany
Adverse event/organ system | Patients with NCI CTC grade [n (%)] | |||
|---|---|---|---|---|
T* | T + CT** | T + HT*** | Total | |
Hematological | ||||
Hemoglobin decreased | - | 13 (1%) | - | 13 (1%) |
WBC decreased | 1 (0%) | 57 (4%) | - | 58 (3%) |
Granulocytes decreased | 1 (0%) | 16 (1%) | 1 (0%) | 18 (1%) |
Non-hematological | ||||
Dyspnea | 1 (0%) | 18 (1%) | 1 (0%) | 20 (1%) |
Pain | 2 (1%) | 16 (1%) | 3 (1%) | 21 (1%) |